EB71 Lisa Cheng – Token Sales And Crowdfunding In The Cryptocurrency Space – Video

Posted on by


EB71 Lisa Cheng - Token Sales And Crowdfunding In The Cryptocurrency Space
Support the show, consider donating: 3B9A9LPxu4VACuobjcqqQBGEng4YseW8SB (http://bit.ly/1CJK4GE) Creating a new token and selling it to fund the development of software has become a ...

By: Epicenter Bitcoin

Link:

EB71 Lisa Cheng - Token Sales And Crowdfunding In The Cryptocurrency Space - Video

Cancer shock for Workington Comets speedway rider Hansen

Posted on by

Last updated at 08:05, Thursday, 26 March 2015

Workington Comets No.1 Kenneth Hansen has pulled out of their season-opening challenge meeting at Redcar tonight (7.30pm start) after being diagnosed with testicular cancer.

Kenneth Hansen

Comets will use rider replacement for the 27-year-old Dane in the first leg of the A66 Trophy at the Bears Media Prima Arena tonight and in Saturdays return leg at the Zebra Claims Stadium.

Hansen has returned to Denmark to begin treatment and has pulled out of at least the next two weeks after his diagnosis yesterday.

Comets owner Laura Morgan said: Kenneth unfortunately will not be taking part in any meetings this weekend after this awful news.

I was really impressed with all of the lads at the press and practice session and Kenneth was no exception. He quickly found a fast line around the track despite not having ridden at Workington for eight years.

I know the supporters will join us in wishing Kenneth a speedy recovery and hope to see him in a Comets jacket soon.

Hansen first rode for Comets in 2007 but lost his place after picking up an injury.

Prior to the news breaking last night, Morgan said she had been looking forward to the start of the season after a tough winter break.

More here:

Cancer shock for Workington Comets speedway rider Hansen

Canucks Reassign Adam Clendening to Comets

Posted on by

March 25, 2015 - American Hockey League (AHL) Utica Comets Vancouver Canucks General Manager Jim Benning announced today that the Canucks have reassigned defenseman Adam Clendening to the AHL Utica Comets. In addition, Utica Comets Director of Hockey Operations Pat Conacher announced today that the Comets have reassigned forward Patrick Kennedy to the ECHL's Kalamazoo Wings from the Comets.

Clendening, 22, has appeared in 17 games with the Canucks this season registering two assists (0-2-2) and eight penalty minutes. He has also split time this season with the Chicago Blackhawks and Rockford IceHogs. He collected two points (1-1-2) in four games with Chicago and 13 points (1-12-13) in 38 games with Rockford. In 2013-14 he was named an AHL First Team All-Star and, in 2012-13, was named a second team AHL All-Star and Rockford's Rookie of the Year.

The Niagara Falls, New York native was acquired from Chicago in exchange for Gustav Forsling on January 29, 2015. He was originally selected by Chicago in the second round, 36th overall in the 2011 NHL Entry Draft.

Kennedy, 25, has appeared in five games this season as part of three separate call-ups with Utica. He has appeared in 25 games and has registered 21 points (nine goals, 12 assists) with Evansville this season. After being traded to the Kalamazoo Wings on March 11, he has recorded two points (1-1-2) in four games for his new team.

After starting last season with the Icemen, Kennedy was signed by the Comets and played in 40 AHL games with Utica. He recorded a goal and four assists with 10 penalty minutes. A native of Dorchester, ON, Kennedy played his college hockey in central New York at Cornell University (2007-11).

For a complete schedule of Utica Comets games, as well as ticketing information, visit http://www.uticacomets.com.

Discuss this story on the American Hockey League message board... Digg this story Add to Del.icio.us

See the article here:

Canucks Reassign Adam Clendening to Comets

Blue Comets edge Cougars on PKs

Posted on by

ASHEBORO The Asheboro and Southwestern Randolph High School varsity soccer teams faced off Wednesday and it came down to the last second or, more accurately, the last kick.

The Blue Comets edged the Cougars 3-2 on penalty kicks at Lee J. Stone Stadium to take the outright Mid-Piedmont Conference lead.

We knew it would be a to-the-wire game, said Blue Comets coach David Parrish, whose team improved to 4-0 in the conference, 4-2 overall. Theyre a great team. Theyre well-coached, theyre disciplined and theyre very fast. We played really good team defense and rotated players on (Deisi Hernandez). Weve been focusing on team soccer.

With the score knotted at 2-all after both 10-minute overtime periods, it came down to five penalty kicks for each team.

AHS went first with Meredith Priest nailing a shot into the left side of the net. SWRs Sarah Teague answered with a similar shot. The Blue Comets Faith Shrewsbury made her first shot, but the official blew his whistle as she went early. Her second try hit off the crossbar. The Cougars Aranza Gallagos saw her attempt hit off the left post, but AHS Riley Clark kicked hers off the right post and it was still 1-1.

The Cougars Deisi Hernandez sank a shot into the left side of the net for a 2-1 lead, but Krystal Jaimes did the same for AHS. Blue Comets keeper Emily Skoglund blocked Bri Cross shot, keeping the PKs at two apiece.

Julia Otranto gave AHS the edge, sinking hers into the right side of the net.

It game down to keeper versus keeper as SWRs Cassie Kopf took the final PK. Skoglund blocked it, giving the Blue Comets the win.

This was just a team effort, said Skoglund, who got the wind knocked out of her with a hard-kicked ball in the first half. Thats how we got here as a team. We just needed to keep fighting the fight. I needed to make stops and they needed to make goals as a team. This shows we have a bright future.

I just told them, Believe, (before the PKs), Parrish said. Thats been our motto this year. I try not to single any one player out. Were gaining confidence. Southwestern Randolph was our kryptonite last year. We needed this.

Go here to read the rest:

Blue Comets edge Cougars on PKs

Cure Psoriasis Naturally – Qigong Stress Exercises – Oxygen Circulation Stretching – Video

Posted on by


Cure Psoriasis Naturally - Qigong Stress Exercises - Oxygen Circulation Stretching
http://www.psoriasisdiary.com/heal - Click that link to download my free healing Psoriasis guide. http://www.psoriasisdiary.com/mentor - Click that link to find out more about an in-depth personal,...

By: PsoriasisDiary

Read the original:

Cure Psoriasis Naturally - Qigong Stress Exercises - Oxygen Circulation Stretching - Video

Boehringer reports positive results from Phase II psoriasis trial

Posted on by

PBR Staff Writer Published 23 March 2015

Boehringer Ingelheim has reported positive results from a Phase II trial that evaluated the efficacy and safety of the new investigational compound BI 655066 versus ustekinumab in patients with moderate-to-severe plaque psoriasis.

The trial showed that nearly double the percentage of patients achieved clear or almost clear skin after 12 weeks of treatment with BI 655066 compared to ustekinumab.

The company said that BI 655066 had similar safety and tolerability compared to ustekinumab.

Primary Phase II analysis from the trial showed that the selective IL-23 inhibitor BI 655066 was superior to ustekinumab, an IL-12/23 inhibitor.

The efficacy analyses were based on pooled dose results for BI 655066 of 90and 180mg.

Probity Medical Research president Alexander Papp said: "The results of this study are compelling. Patients showed significant skin improvement with BI 655066 compared to ustekinumab, a widely acknowledged and accepted standard of treatment for moderate-to-severe psoriasis.

"These results are particularly encouraging given the study focused on a new treatment goal of PASI 90. The results showed that more patients treated with BI 655066 reached this rigorous primary endpoint.

"Furthermore, we saw that patients continued to achieve clear or almost clear skin beyond week 12. Achieving clear or almost clear skin can make a real difference to patients as they have to deal with the daily impact of psoriasis."

During the trial, a total of 166 patients were randomly assigned to one of three dose groups of BI 655066 18mg, 90mg or 180mg, or ustekinumab.

See original here:

Boehringer reports positive results from Phase II psoriasis trial